Company / Operating Cash Flow
CRISPR Therapeutics AG Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$345.0M
FY2025
5-year range
-$495.7M / $539.0M
FY2021-FY2025
Trend
-141.7%
vs FY2024
Sector context
#195 of 214
Health Care
What the data says
Among 214 Health Care companies, CRISPR Therapeutics AG is in the bottom 9% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$496M in FY2022 to $539M in FY2021.
Based on SEC 10-K filings.
-$345M in FY2025.
Declined from -$260M to -$345M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 214This company -$345.0M Sector average $663.6M
▼
-152.0% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 141.7% year-over-year.
- Ranks #195 out of 214 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2021.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$345.0M | -141.7% |
| FY2024 | -$142.8M | +45.2% |
| FY2023 | -$260.4M | +47.5% |
| FY2022 | -$495.7M | -192.0% |
| FY2021 | $539.0M | +326.1% |
| FY2020 | -$238.4M | -520.6% |
| FY2019 | $56.7M | +158.9% |
| FY2018 | -$96.2M | -37.3% |
| FY2017 | -$70.1M | -32.6% |
| FY2016 | -$52.9M | -188.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026